VBL is actively engaged in the development of new Lecinoxoid product candidates. Some of our molecules are at a preliminary stage of in-vitro testing, while other candidates have been advanced to preclinical models and are currently being studied for efficacy and safety. Our preclinical results indicate that several molecules that we are developing may offer higher potency or mechanistic selectivity compared to VB-201.